MARKET

MRK

MRK

Merck & Co
NYSE

Real-time Quotes | Nasdaq Last Sale

80.28
-0.17
-0.21%
After Hours: 80.70 +0.42 +0.52% 19:51 11/23 EST
OPEN
80.61
PREV CLOSE
80.45
HIGH
81.16
LOW
79.38
VOLUME
9.06M
TURNOVER
--
52 WEEK HIGH
92.64
52 WEEK LOW
65.25
MARKET CAP
203.11B
P/E (TTM)
17.66
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
A Trio of Stocks for Growth-Focused Investors
These companies have grown their earnings over the past year
GuruFocus.com · 6h ago
A successful Ebola vaccine delivery shows how a Covid-19 vaccine would work in Africa
“We are not starting from scratch in Africa."
Quartz · 7h ago
Merck To Buy Late-Stage COVID-19 Treatment Company OncoImmune For $425M In Cash
Merck & Co., Inc.
Benzinga · 10h ago
Coronavirus update: FDA OKs Regeneron antibody EUA; AstraZeneca shows positive vaccine results
U.S. cases surpass 12 million as positive vaccine and antibody treatment news provide hope.
Yahoo Finance · 10h ago
Dow Jones Today, Stocks Open Higher; Merck, Regeneron Jump On Covid News; Tesla Nails A Breakout
Regeneron and Gap were early leaders, while Merck topped the Dow Jones today, as stock futures rose on coronavirus vaccine optimism.
Investor's Business Daily · 12h ago
Merck Animal Health Survey Reveals First-Time Dog Owners Need Support
Merck Animal Health, known as MSD Animal Health outside the US and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced a new survey about first-time dog owners and whether or not they were prepared for pet parenthood. Results from the "Embracing Pet Care for Life" survey revealed that taking care of a new pet, especially during a pandemic, may not be as simple as one may think.
PR Newswire · 12h ago
Merck files for licensure of V114 in U.S. and Europe
Merck (MRK) has submitted applications to the FDA and EMA for licensure of V114, its investigational 15-valent pneumococcal conjugate vaccine, for use in adults 18 years of age and older
Seekingalpha · 14h ago
Merck Pays $425 Million For Oncolmmune And Its Developing COVID Therapy
Merck & Co. said Monday that it will pay $425 million for Oncolmmune, a privately-held biotech that has developed a promising treatment for patients suffering a severe form of COVID-19.
TheStreet.com · 14h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRK. Analyze the recent business situations of Merck & Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRK stock price target is 95.58 with a high estimate of 107.00 and a low estimate of 85.00.
EPS
Institutional Holdings
Institutions: 3.14K
Institutional Holdings: 2.00B
% Owned: 78.95%
Shares Outstanding: 2.53B
TypeInstitutionsShares
Increased
1.09K
48.95M
New
221
23.48M
Decreased
923
84.91M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.87%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Chief Executive Officer/President/Director
Kenneth Frazier
Chief Financial Officer/Executive Vice President
Robert Davis
Chief Human Resource Officer/Executive Vice President
Steven Mizell
Executive Vice President/Chief Marketing Officer
Michael Nally
Executive Vice President/General Counsel/Secretary
Jennifer Zachary
Executive Vice President
Sanat Chattopadhyay
Executive Vice President
Frank Clyburn
Executive Vice President
Franklin Clyburn
Executive Vice President
Richard DeLuca
Executive Vice President
Julie Gerberding
Executive Vice President
Roger Perlmutter
Senior Vice President - Finance/Controller
Rita Karachun
Senior Vice President/Chief Compliance Officer
Michael Fleming
Lead Director/Independent Director
Leslie Brun
Independent Director
Thomas Cech
Independent Director
Mary Coe
Independent Director
Pamela Craig
Independent Director
Thomas Glocer
Independent Director
Paul Rothman
Independent Director
Patricia Russo
Independent Director
Christine Seidman
Independent Director
Inge Thulin
Independent Director
Kathy Warden
Independent Director
Peter Wendell
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
11/17/2020
Dividend USD 0.65
12/14/2020
07/28/2020
Dividend USD 0.61
09/14/2020
05/26/2020
Dividend USD 0.61
06/12/2020
01/28/2020
Dividend USD 0.61
03/13/2020
11/19/2019
Dividend USD 0.61
12/13/2019
07/23/2019
Dividend USD 0.55
09/13/2019
05/28/2019
Dividend USD 0.55
06/14/2019
01/29/2019
Dividend USD 0.55
03/14/2019
10/25/2018
Dividend USD 0.55
12/14/2018
07/24/2018
Dividend USD 0.48
09/14/2018
05/22/2018
Dividend USD 0.48
06/14/2018
01/23/2018
Dividend USD 0.48
03/14/2018
11/28/2017
Dividend USD 0.48
12/14/2017
07/26/2017
Dividend USD 0.47
09/14/2017
05/23/2017
Dividend USD 0.47
06/13/2017
03/01/2017
Dividend USD 0.47
03/13/2017
11/22/2016
Dividend USD 0.47
12/13/2016
07/26/2016
Dividend USD 0.46
09/13/2016
05/24/2016
Dividend USD 0.46
06/13/2016
02/23/2016
Dividend USD 0.46
03/11/2016
11/24/2015
Dividend USD 0.46
12/11/2015
07/22/2015
Dividend USD 0.45
09/11/2015
05/26/2015
Dividend USD 0.45
06/11/2015
02/24/2015
Dividend USD 0.45
03/12/2015
11/25/2014
Dividend USD 0.45
12/11/2014
07/23/2014
Dividend USD 0.44
09/11/2014
05/27/2014
Dividend USD 0.44
06/12/2014
02/25/2014
Dividend USD 0.44
03/13/2014
11/26/2013
Dividend USD 0.44
12/12/2013
07/25/2013
Dividend USD 0.43
09/12/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MRK
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Merck & Co., Inc. stock information, including NYSE:MRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRK stock methods without spending real money on the virtual paper trading platform.